Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates

结构引导抗体靶向淀粉样蛋白聚集体中预先选择的表位

基本信息

  • 批准号:
    10599101
  • 负责人:
  • 金额:
    $ 26.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-01 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Amyloidogenic protein aggregation is a key event in seemingly disparate biological phenomena, including those ranging from bacterial biofilms to neurodegenerative diseases. Intriguingly, amyloidogenic proteins do not form aggregates with a single 3D structure, but rather with several related yet distinct 3D structures that are linked to unique biological activities (akin to prion strains). How these structurally-unique aggregates mediate different toxic or beneficial activities is one of the most important questions in the protein aggregation field. Conformational antibodies specific for amyloidogenic aggregates are invaluable for investigating this intriguing problem and, more generally, for their potential use as disease-specific diagnostic and therapeutic agents. The utility of such antibodies stems from their ability to sensitively detect specific types of protein aggregates and selectively interfere with their biological activities. However, these types of antibodies are difficult to generate because of issues common to many antigens (immunodominant epitopes) and those specific to protein aggregates (multivalent, highly hydrophobic and, in some cases, kinetically unstable). The goals of this proposal are to develop structure-guided approaches for in vitro generation of antibodies against six classes of predicted conformational epitopes in amyloidogenic aggregates, and to use these antibodies to evaluate conformational differences between disease-associated aggregates formed in vivo. The predicted epitopes – which include the leading candidates for generic antibody epitopes in oligomers and fibrils – have not been specifically targeted or verified previously using monoclonal antibodies. We will primarily target a- synuclein (associated with Parkinson’s disease), which forms multiple types of oligomers and fibrils. These studies will address four key fundamental (Q1, Q2) and methodological (Q3, Q4) questions. 1) Which generic classes of predicted conformational antibody epitopes exist in oligomers and fibrils of a-synuclein and other amyloidogenic proteins? 2) Which protein-specific classes of predicted conformational epitopes exist in different structural (strain) variants of a-synuclein aggregates? 3) What are optimal design parameters for generating in vitro antibody libraries that maximize the likelihood of isolating antibodies with high specificity in addition to high affinity? 4) What are the most effective in vitro methods for targeting antibody libraries to pre- selected epitopes in protein aggregates in order to overcome common problems associated with immunodominant epitopes and poor antigen quality? These proposed studies are based on multiple discoveries in the Tessier lab: i) novel in vitro library design and sorting methods for isolating yeast-displayed antibodies with extremely high specificity; ii) bioinformatics methods for predicting antibody specificity; and iii) identification of multiple classes of conformational epitopes in Ab fibrils. These discoveries provide a strong basis for rationally generating antibodies against diverse types of amyloidogenic aggregates and for providing key insights into conformational differences between protein aggregates linked to unique human disorders.
淀粉样蛋白聚集在看似不同的生物现象中是一个关键事件,包括

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter M Tessier其他文献

Peter M Tessier的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter M Tessier', 18)}}的其他基金

Neuronal Silencing of ATXN3 Using Peripherally Administered Antibody/ASO Conjugates That Penetrate the Blood-Brain Barrier
使用可穿透血脑屏障的外周给药抗体/ASO 缀合物对 ATXN3 进行神经元沉默
  • 批准号:
    10646563
  • 财政年份:
    2023
  • 资助金额:
    $ 26.97万
  • 项目类别:
Mutational Analysis of Tradeoffs between Receptor Affinity and Antibody Escape for SARS-CoV-2 Variants of Concern
SARS-CoV-2 相关变体的受体亲和力与抗体逃逸之间权衡的突变分析
  • 批准号:
    10510890
  • 财政年份:
    2022
  • 资助金额:
    $ 26.97万
  • 项目类别:
Mutational Analysis of Tradeoffs between Receptor Affinity and Antibody Escape for SARS-CoV-2 Variants of Concern
SARS-CoV-2 相关变体的受体亲和力与抗体逃逸之间权衡的突变分析
  • 批准号:
    10647809
  • 财政年份:
    2022
  • 资助金额:
    $ 26.97万
  • 项目类别:
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates
结构引导抗体靶向淀粉样蛋白聚集体中预先选择的表位
  • 批准号:
    10387799
  • 财政年份:
    2020
  • 资助金额:
    $ 26.97万
  • 项目类别:
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates
结构引导抗体靶向淀粉样蛋白聚集体中预先选择的表位
  • 批准号:
    10372055
  • 财政年份:
    2020
  • 资助金额:
    $ 26.97万
  • 项目类别:
Design of Antibody Fragments Specific For Amyloidogenic Aggregates
淀粉样蛋白形成聚集物特异性抗体片段的设计
  • 批准号:
    9582129
  • 财政年份:
    2014
  • 资助金额:
    $ 26.97万
  • 项目类别:
Design of antibody fragments specific for amyloidogenic aggregates
淀粉样蛋白形成聚集物特异性抗体片段的设计
  • 批准号:
    8823800
  • 财政年份:
    2014
  • 资助金额:
    $ 26.97万
  • 项目类别:
Design of antibody fragments specific for amyloidogenic aggregates
淀粉样蛋白形成聚集物特异性抗体片段的设计
  • 批准号:
    8631424
  • 财政年份:
    2014
  • 资助金额:
    $ 26.97万
  • 项目类别:
Structural basis of species-specific infectivities of two prion strains
两种朊病毒株物种特异性感染性的结构基础
  • 批准号:
    7843591
  • 财政年份:
    2009
  • 资助金额:
    $ 26.97万
  • 项目类别:
Structural basis of species-specific infectivities of two prion strains
两种朊病毒株物种特异性感染性的结构基础
  • 批准号:
    7641394
  • 财政年份:
    2009
  • 资助金额:
    $ 26.97万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 26.97万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 26.97万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 26.97万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.97万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 26.97万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 26.97万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 26.97万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 26.97万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 26.97万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 26.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了